Sadao Nakane
Taisho Pharmaceutical Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sadao Nakane.
Mutation Research | 1995
Hiroshi Suzuki; Tomotake Ikeda; Takehiro Yamagishi; Shiro Nakaike; Sadao Nakane; Motoyasu Ohsawa
Eukaryotic topoisomerase II (Topo-II) inhibitors such as etoposide, adriamycin and mitoxantrone, which commonly stabilize the cleavable complex of the enzyme and DNA, have been found to efficiently induce chromosome-type aberrations (mainly breaks and exchanges) in cultured Chinese hamster lung fibroblastic cells (CHL cells). To clarify whether the induction of chromosome-type aberrations is mediated by stabilization of the cleavable complex, the present study investigated (1) the correlation between the induction of chromosome-type aberrations and the amount of cleavable complex formed; and (2) the ATP dependence of the Topo-II inhibitor-induced chromosome-type aberrations due to the ATP requirement of cleavable complex formation by Topo-II. First, in cells treated with the Topo-II inhibitors, (etoposide, adriamycin) and aclarubicin, an antagonist of the inhibitor of cleavable complex formation, the frequency of chromosome-type aberrations decreased dose-dependently with aclarubicin, in contrast to an increase of chromatid-type aberrations. The formation of the cleavable complex was further established by a proteinase K/SDS precipitation assay for cleaved double-strand DNA in a cell-free system and in CHL cells. Results from both experiments showed that aclarubicin caused a dose-dependent suppression of the accumulation of the cleavable complex induced by etoposide, which corresponded particularly well to the reduction of chromosome-type aberrations in etoposide-treated cells. In ATP-depleted cells simultaneously treated with etoposide and dinitrophenol (DNP), chromosome-type aberrations were reduced as compared with DNP-untreated cells, in contrast to an increase of chromatid exchanges in the cells. This means that etoposide-induced chromosome-type aberrations in ATP-depleted cells may be attributable to incompleteness of Topo-II activities to form DNA double-strand breaks. The present findings indicate that the stabilization of the cleavable complex on Topo-II is closely associated with the induction of chromosome-type aberrations.
Folia Pharmacologica Japonica | 1974
Sadao Nakane; Takeshi Sakai
本研究において,自律神経薬ほか諸種薬物の潰瘍形成と胃液分泌およびPSB漏出量におよぼす影響を検討し,以下の結果を得た.1)本実験で,phenoxybenzamineを除き,ストレス潰瘍抑制作用を示した薬物は,潰瘍抑制量で胃液分泌減少とpH上昇作用を示した.このことは,ストレス潰瘍抑制には胃液分泌の抑制が重要な要因であることを示唆するものと考えられる.2)atropineは,潰瘍抑制量において,ストレスによるPSB量減少に対し,少くとも増強作用を示さなかった.また,propranolol,DCIおよびchlorpromazineは,ストレスによるPSB量減少に対し,むしろ阻止的であった.これより,ストレスによる胃粘膜血流の阻止ないし抑制が抗潰瘍作用の一因となると考えられる.
Chemical & Pharmaceutical Bulletin | 1979
Kazuaki Kyogoku; Katsuo Hatayama; Sadakazu Yokomori; Ryuichi Saziki; Sadao Nakane; Michitada Sasajima; Jiro Sawada; Masahiro Ohzeki; Ichiro Tanaka
Journal of Toxicological Sciences | 1995
Toshiji Igarashi; Sadao Nakane; Toshikazu Kitagawa
Journal of Toxicological Sciences | 1981
Yasuo Tarumoto; Satoshi Abe; Yoshifumi Tsutsui; Sadao Nakane; Michitada Sasajima; Masahiro Ohzeki
Folia Pharmacologica Japonica | 1978
Michitada Sasajima; Sadao Nakane; Ryuichi Saziki; Hideo Saotome; Katsuo Hatayama; Kazuaki Kyogoku; Ichiro Tanaka
Biological & Pharmaceutical Bulletin | 1994
Hiroshi Suzuki; Sadao Nakane
Japanese Journal of Pharmacology | 1980
Hironaka Aihara; Michio Kurachi; Sadao Nakane; Michitada Sasajima; Masahiro Ohzeki
Japanese Journal of Pharmacology | 1984
Masaaki Kimura; Ryuichi Saziki; Iwao Arai; Yasuo Tarumoto; Sadao Nakane
Japanese Journal of Pharmacology | 1974
Sadao Nakane; Takeshi Sakai